CA-125 Tumour Marker: Normal Levels, Causes and Interpretation

Laboratory Diagnosticsupdated

Reviewed by the LabReadAI medical team
CA-125 Tumour Marker: Normal Levels, Causes and Interpretation

An elevated CA-125 result is one of the most anxiety-provoking findings for a woman. Before alarming conclusions are drawn, the most important thing to understand is this: CA-125 rises in dozens of entirely benign conditions, while ovarian cancer at early stages frequently produces a normal result. Here is what this marker actually measures and in which situations it is genuinely informative.

What Is CA-125 and Why Is It Ordered

CA-125 (cancer antigen 125) is a high-molecular-weight glycoprotein produced by coelomic epithelial cells: the mesothelium of the peritoneum, pleura and pericardium, and the epithelium of the fallopian tubes, endometrium and endocervix. Under normal conditions, only trace amounts circulate in the blood. When these cells are inflamed, irritated or malignantly transformed, CA-125 secretion into the bloodstream rises substantially.

Like CEA, CA-125 is a monitoring marker, not a diagnostic one:

  • Primary application — monitoring treatment of epithelial ovarian cancer. CA-125 is elevated in approximately 80% of patients with advanced disease. Its dynamics following surgery and chemotherapy are one of the key criteria of treatment response.
  • Early recurrence detection — rising CA-125 precedes clinical symptoms and CT evidence of ovarian cancer recurrence by an average of 3–5 months.
  • Staging — a very high baseline level correlates with disease extent.

What CA-125 cannot do:

  • Screen for ovarian cancer in healthy women — sensitivity and specificity are insufficient
  • Confirm or exclude cancer on primary workup without additional data (ultrasound, clinical findings)
  • Replace biopsy in establishing a diagnosis

The test is part of the standard tumour marker panel and is ordered by an oncologist, gynaecologist, or gynaecological oncologist.

CA-125 Normal Range

The standard reference range for CA-125 in adult women:

Status Normal range
Premenopausal women < 35 U/mL
Postmenopause < 20 U/mL (some laboratories)
Pregnant women (1st trimester) may reach 100–200 U/mL — physiological
Men < 35 U/mL

In men, CA-125 is detectable at low concentrations as a normal finding — the marker is not exclusively female, but its clinical significance in men is limited, chiefly to pleural mesothelioma and pericarditis.

Key interpretation points:

  • 35–200 U/mL — mild elevation. In the vast majority of premenopausal women without an oncological history, this reflects a benign cause.
  • > 200 U/mL — significant elevation, particularly in combination with a pelvic mass and postmenopausal status — urgent exclusion of ovarian cancer is required.
  • > 1000 U/mL — almost invariably a malignant process, frequently with evidence of peritoneal dissemination.

CA-125 rises predictably during the first days of menstruation (up to 2–3 times the upper limit). This is a physiological variation, not pathology. The test should therefore not be drawn during a period.

Which Cancers Are Associated with Elevated CA-125

CA-125 is non-specific — it rises in several malignancy types, not only gynaecological ones.

Ovarian cancer — the primary clinical application. CA-125 is elevated in approximately 50% of patients with stage I disease and in 80–90% with stage III–IV epithelial ovarian cancer. High-grade serous adenocarcinoma produces the most pronounced elevations. Mucinous ovarian tumours raise CA-125 far less consistently — CA 19-9 is a more informative marker for that subtype.

Endometrial cancer — elevated in 20–30% of patients, more commonly in advanced disease.

Fallopian tube cancer and primary peritoneal cancer — anatomically close to the ovaries and express CA-125 as actively.

Pancreatic, gastric, colorectal, lung and breast cancers — CA-125 may be mildly elevated in some patients but is not the marker of choice for these tumours.

Pleural and peritoneal mesothelioma — a malignancy in which CA-125 is frequently markedly elevated in both sexes.

Non-Oncological Causes of Elevated CA-125

This is the most critically underappreciated category: in premenopausal women, the majority of CA-125 elevations are not cancer.

Endometriosis — one of the most common causes of chronically elevated CA-125, often reaching 50–300 U/mL. Ectopic endometrial tissue produces CA-125 just as actively as ovarian cancer cells. In endometriosis, the level correlates with disease stage — stages III–IV produce the highest values.

Uterine fibroids — mild elevation, particularly with large or submucosal fibroids.

Benign ovarian cysts — follicular cysts and corpus luteum cysts can transiently raise CA-125.

Acute pelvic inflammatory disease — salpingitis, pelvioperitonitis. CA-125 is substantially elevated due to peritoneal mesothelial activation.

Pregnancy — physiologically elevated CA-125 in the first trimester is related to chorionic villus formation and requires no further investigation.

Liver disease — liver cirrhosis and acute hepatitis. The peritoneal mesothelium actively expresses CA-125 in the presence of ascites or hepatic inflammation.

Other causes: pericarditis, pleuritis, ascites of any origin, renal failure, autoimmune diseases. Assessment of kidney function and liver function is part of the workup for unexplained CA-125 elevation.

How to Prepare for a CA-125 Blood Test

CA-125 is measured in venous blood. A few practical rules improve the reliability of results:

  • Cycle timing — avoid testing during menstruation and the first 3–4 days after it ends: the physiological rise during a period can create a falsely elevated result. The optimal window is from cycle day 5 onwards.
  • Fasting — blood is drawn 8–12 hours after the last meal, for reproducibility in serial monitoring.
  • Active infections or inflammation — CA-125 may be transiently elevated during a urinary tract infection, respiratory illness, or pelvic inflammatory disease. If the test is not urgent, wait until recovery.
  • One laboratory for the entire monitoring course: different immunoassay platforms yield non-comparable absolute values.
  • High-dose biotin — discontinue 48 hours before the draw.

A note on initial workup: an isolated CA-125 without pelvic ultrasound is poorly informative. Gynaecologists assess CA-125 alongside transvaginal ultrasound: the combination of elevated CA-125 and a suspicious adnexal mass on imaging is an indication for surgical clarification.

CA-125 Trends: How to Interpret Serial Results

During ovarian cancer monitoring, the trend is interpreted through several key patterns:

Normalisation after treatment — following radical surgery and chemotherapy, CA-125 should fall to below 35 U/mL. Failure to normalise within the first 3–6 months suggests residual disease or insufficient treatment response.

Progressive decline — even if CA-125 remains above normal after initial treatment cycles, a sustained downward trend indicates chemotherapy effectiveness. Treatment should not be changed on the basis of a single elevated value.

Rise from nadir — a doubling of CA-125 from its lowest confirmed value on two consecutive measurements four weeks apart is the internationally accepted criterion for biochemical recurrence. This triggers imaging workup even in the absence of clinical symptoms.

"Flare" reaction — a transient CA-125 rise in the first one to two chemotherapy cycles does not indicate treatment failure; it reflects antigen release from dying tumour cells.

No CA-125 result is ever assessed without clinical context. Any significant elevation — especially in a postmenopausal woman with symptoms — warrants timely medical review.

When to See a Doctor

Urgent referral to a gynaecologist or gynaecological oncologist when:

  • CA-125 above 200 U/mL in a postmenopausal woman, especially with a pelvic mass on ultrasound
  • Any CA-125 elevation combined with lower abdominal pain, bloating, urinary frequency, or unexplained weight loss
  • Rising CA-125 in a patient with treated ovarian cancer in remission

Scheduled gynaecology appointment when:

  • CA-125 35–100 U/mL in a premenopausal woman without symptoms — exclude endometriosis, pelvic inflammatory disease, benign cyst
  • Mildly elevated chronic values with known endometriosis — assess disease activity

No immediate action needed:

  • Mild elevation (< 50 U/mL) during or immediately after menstruation — retest mid-cycle
  • Moderate elevation during an acute infection — retest after recovery

An elevated CA-125 is not a diagnosis — it is a prompt for a structured diagnostic workup. Do not interpret tumour markers on your own; see a gynaecologist who can assess the full clinical picture.

This content is for informational purposes only and does not replace professional medical advice.

Frequently asked questions

  • Yes, and this is one of the marker's key limitations. At early stages (I–II), CA-125 is normal in approximately half of patients with ovarian cancer. Mucinous and clear cell histological subtypes raise CA-125 less reliably than serous tumours. A normal result does not exclude cancer — diagnosis is built on ultrasound, CT, and histology, not on the tumour marker level alone.

  • In endometriosis, CA-125 is frequently elevated to 50–300 U/mL, occasionally higher. The level correlates with disease extent: stages III–IV produce the highest values. Elevated CA-125 alone does not confirm endometriosis — the diagnosis requires laparoscopy. CA-125 dynamics can be used to assess response to hormonal therapy. Women with cycle irregularities alongside endometriosis often have prolactin and sex hormones checked at the same time.

  • No. Large clinical trials, including the UKCTOCS study, showed that regular CA-125 screening in healthy women at average risk does not reduce ovarian cancer mortality and leads to many unnecessary operations due to false-positive results. Screening with CA-125 is justified only in women at high genetic risk — BRCA1/BRCA2 mutation carriers — under specialist oncological supervision.

  • The only definitive method is histological verification (biopsy or surgery). Indirect indicators pointing toward malignancy include postmenopausal status, bilateral ovarian involvement on ultrasound, CA-125 > 200 U/mL, ascites, and a suspicious sonographic appearance (solid component, septations, papillary projections). A low HCG level rules out choriocarcinoma as a cause.

  • Ideally from cycle day 5–7, after menstruation has ended. During a period, CA-125 rises two to three times above the normal baseline — a result obtained during menstruation may trigger unnecessary concern. When testing is for treatment monitoring rather than primary diagnosis, cycle timing is less critical; consistent conditions at each measurement matter more.

  • When ovarian cancer is suspected, CEA and CA 19-9 are often added — particularly for mucinous tumour subtypes, which express little CA-125 but actively secrete CA 19-9. For suspected germ cell tumours, AFP and HCG are included. The composition of the panel is determined by the physician based on clinical presentation and ultrasound findings.

#Tumour Markers#CEA Tumour Marker#CA 19-9 Tumour Marker#AFP Tumour Marker

For informational purposes only

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Please consult a healthcare professional for medical guidance.

Decode your tests with AIUpload a photo or PDF — get a clear explanation of every value in minutes. Start decoding